Dose Cancer Research Results

Dose, Dosage: Click to Expand ⟱
Source:
Type:
Drug dosage vs efficacy, and actual dosage number of research papers.
HCC, Hepatocellular Carcinoma: Click to Expand ⟱
Hepatocellular Carcinoma
Scientific Papers found: Click to Expand⟱
5259- 3BP,    Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP
- in-vivo, HCC, NA
ATP↓, TumCD↑, toxicity↓, eff↑, tumCV↓, Dose↝,
5269- 3BP,    The anti-metabolite KAT/3BP has in vitro and in vivo anti-tumor activity in lymphoma models.
- in-vitro, HCC, NA
toxicity↑, eff↝, eff↑, Glycolysis↓, HK2↓, AIF↑, Apoptosis↑, NK cell↑, toxicity↑, toxicity↓, Dose↝, AntiTum↑,
5716- BF,    Pilot Study of Huachansu in Patients with Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, or Pancreatic Cancer
- Trial, NSCLC, NA - Trial, PC, NA - Trial, HCC, NA
Dose↝, toxicity↓, other↓, QoL↑, OS?,
5846- CAP,    Capsaicin Alters the Expression of Genetic and Epigenetic Molecules In Hepatocellular Carcinoma Cell
- in-vitro, HCC, HepG2
Dose↝, miR-126↑, Ki-67↓, PI3K↓, mTOR↓, Akt↑, eff↑, Casp3↑,
5892- CAR,  SRF,    Carvacrol potentiates immunity and sorafenib anti-cancer efficacy by targeting HIF-1α/STAT3/ FGL1 pathway: in silico and in vivo study
- in-vivo, HCC, NA
Hif1a↓, AFP↑, hepatoP↑, STAT3↓, JAK2↓, *CD8+↑, ChemoSen↑, Dose↝, angioG↓,
5891- CAR,  SRF,    Carvacrol enhances anti-tumor activity and mitigates cardiotoxicity of sorafenib in thioacetamide-induced hepatocellular carcinoma model through inhibiting TRPM7
- in-vivo, HCC, NA
eff↑, OS↑, hepatoP↑, AFP↓, NOTCH↓, cycD1/CCND1↓, Bcl-xL↑, Casp3↑, TRPM7↓, Dose↝,
7198- GBE,    Ginkgo biloba extract suppresses hepatocellular carcinoma progression by inhibiting the recruitment of myeloid-derived suppressor cells through reduced CXCL1 secretion via SRC downregulation
- vitro+vivo, HCC, NA
TumCG↓, Src↓, CXCL1↓, Dose↝,
6564- Ger,    Effect of geraniol on fatty-acid and mevalonate metabolism in the human hepatoma cell line Hep G2
- in-vitro, HCC, HepG2
TumCG↓, HMG-CoA↓, TumCP↓, eff↑, Dose↝,
7264- Gink,    Anti-tumor effect of ginkgetin on human hepatocellular carcinoma cell lines by inducing cell cycle arrest and promoting cell apoptosis
- vitro+vivo, HCC, HepG2 - NA, HCC, SK-HEP-1
tumCV↓, TumCCA↓, Casp3↑, Cyt‑c↑, TumCG↓, Dose↝,
8103- KAE,    The dietary flavonoid kaempferol effectively inhibits HIF-1 activity and hepatoma cancer cell viability under hypoxic conditions
- in-vitro, HCC, HUH7
Dose↝, HIF-1↓, tumCV↓,
2489- metroC,  capec,    Long-lasting response with metronomic capecitabine in advanced hepatocellular carcinoma
- Case Report, HCC, NA
Dose↝, OS↑, TumVol↓, AFP↓,
2486- metroC,  capec,    Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases
- Case Report, HCC, NA
OS↑, eff↝, Dose↝, AFP↓, Dose↝, TumVol↓, AFP↓,
5605- NaHCO3,    A nonrandomized cohort and a randomized study of local control of large hepatocarcinoma by targeting intratumoral lactic acidosis
- Trial, HCC, NA
eff↑, Dose↝, other↓, OS↑, toxicity↓, AntiCan↓,
2382- PBG,    Integration with Transcriptomic and Metabolomic Analyses Reveals the In Vitro Cytotoxic Mechanisms of Chinese Poplar Propolis by Triggering the Glucose Metabolism in Human Hepatocellular Carcinoma Cells
- in-vitro, HCC, HepG2
TumCP↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, GLUT1↓, GLUT2↓, LDHA↓, HK2↓, PKM2↓, PFK↓, Dose↝,
1939- PL,    Piperlongumine selectively kills hepatocellular carcinoma cells and preferentially inhibits their invasion via ROS-ER-MAPKs-CHOP
- in-vitro, HCC, HepG2 - in-vitro, HCC, HUH7 - in-vivo, NA, NA
TumCMig↓, TumCI↓, ER Stress↑, selectivity↑, tumCV↓, ROS↑, GSH↓, eff↓, Ca+2↑, MAPK↑, CHOP/DDIT3↑, Dose↝,
6810- RF,    SUMMARY OF SAFETY AND PROBABLE BENEFIT (SSPB)
- Trial, HCC, NA
Dose↝, Dose↝, Dose↝, OS↑,
6808- RF,    Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced hepatocellular carcinoma
- Trial, HCC, NA
OS↑, *toxicity↓, Dose↝, TumCG↓, Dose↝, Dose↝, Dose↝, eff↑,
6807- RF,    Tumour-specific amplitude-modulated radiofrequency electromagnetic fields induce differentiation of hepatocellular carcinoma via targeting Cav3.2 T-type voltage-gated calcium channels and Ca2+ influx
- NA, HCC, NA
TumVol↓, Ca+2↑, TumCG↓, Dose↝,
4726- Se,  Oxy,    Oxygen therapy accelerates apoptosis induced by selenium compounds via regulating Nrf2/MAPK signaling pathway in hepatocellular carcinoma
- in-vivo, HCC, NA
eff↝, NRF2↓, p‑p38↑, Apoptosis↑, eff↑, TumVol↓, other↝, toxicity↓, Dose↝, NRF2↝, HO-1↓, Catalase↓, SOD↓, e-pH↓, pH∅, MAPK↑, eff↑,
2485- VitC,  TACE,    High-Dose Vitamin C Promotes Regression of Multiple Pulmonary Metastases Originating from Hepatocellular Carcinoma
- Case Report, HCC, NA
ROS↑, Dose↝, Dose↝, TumCG↓, Remission↑,

Showing Research Papers: 1 to 20 of 20

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 20

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↓, 1,   GSH↓, 1,   HO-1↓, 1,   NRF2↓, 1,   NRF2↝, 1,   ROS↑, 2,   SOD↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   ATP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

GlucoseCon↓, 1,   GLUT2↓, 1,   Glycolysis↓, 2,   HK2↓, 2,   HMG-CoA↓, 1,   lactateProd↓, 1,   LDHA↓, 1,   PFK↓, 1,   PKM2↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↑, 1,   Apoptosis↑, 2,   Bcl-xL↑, 1,   Casp3↑, 3,   Cyt‑c↑, 1,   MAPK↑, 2,   p‑p38↑, 1,   TumCD↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↓, 2,   other↝, 1,   tumCV↓, 4,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   ER Stress↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 1,   TumCCA↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

mTOR↓, 1,   NOTCH↓, 1,   PI3K↓, 1,   Src↓, 1,   STAT3↓, 1,   TRPM7↓, 1,   TumCG↓, 6,  

Migration(tgid=13) ⓘ

Ca+2↑, 2,   Ki-67↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   HIF-1↓, 1,   Hif1a↓, 1,   miR-126↑, 1,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CXCL1↓, 1,   JAK2↓, 1,   NK cell↑, 1,  

Cellular Microenvironment(tgid=17) ⓘ

pH∅, 1,   e-pH↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   Dose↝, 27,   eff↓, 1,   eff↑, 9,   eff↝, 3,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

AFP↓, 4,   AFP↑, 1,   Ki-67↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↓, 1,   AntiTum↑, 1,   hepatoP↑, 2,   OS?, 1,   OS↑, 6,   QoL↑, 1,   Remission↑, 1,   toxicity↓, 5,   toxicity↑, 2,   TumVol↓, 4,  
Total Targets: 74

Pathway results for Effect on Normal Cells:


Functional Outcomes(tgid=23) ⓘ

toxicity↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

CD8+↑, 1,  
Total Targets: 2

Scientific Paper Hit Count for: Dose, Dosage
3 EMF
2 3-bromopyruvate
2 Carvacrol
2 Sorafenib (brand name Nexavar)
2 metronomic chemo
2 capecitabine
1 Bufalin/Huachansu
1 Capsaicin
1 Ginkgo biloba
1 Geraniol
1 Ginkgetin
1 Kaempferol
1 Bicarbonate(Sodium)
1 Propolis -bee glue
1 Piperlongumine
1 Selenium
1 Oxygen, Hyperbaric
1 Vitamin C (Ascorbic Acid)
1 Transarterial Chemoembolization
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:10  Cells:%  prod#:%  Target#:1114  State#:%  Dir#:4
  wNotes=0  sortOrder:rid,rpid

 

Home Page